Alimera Sciences

Retinal Disease
is Our Focus

Moving the back of the eye to the forefront
of research and development.

Learn more about our goals »

ILUVIEN: Investigational Treatment for DME

ILUVIEN® Fluocinolone acetonide intravitreal insert .019 mg

ILUVIEN® has received its marketing authorization approval in Austria, France, Germany, Portugal, Spain and the United Kingdom and is going through the national phase in the approval process in Italy. Alimera Sciences is still seeking approval in the United States.

Learn more >

Diabetes is the leading cause of new cases of blindness in adults

DIABETES and
VISION LOSS

Diabetes is the leading cause of new cases of blindness in adults.

Learn More >

Latest News

View All Recent News »

Alimera Sciences Reports First Quarter 2013 Financial Results

May 09, 2013 --  Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced financial results for the first quarter ended March 31,...

Read More »

Alimera Sciences Secures $20 Million Debt Facility

May 08, 2013 --  Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that its United Kingdom subsidiary, Alimera Sciences...

Read More »

Alimera Sciences Announces First Patient Treated With Commercially Available ILUVIEN®

May 07, 2013 --  Alimera Sciences, Inc., (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that ILUVIEN®, the first sustained release...

Read More »